Beyond histology: Translating tumor genotypes into clinically effective targeted therapies

Catherine B. Meador, Christine M. Micheel, Mia A. Levy, Christine M. Lovly, Leora Horn, Jeremy L. Warner, Douglas B. Johnson, Zhongming Zhao, Ingrid A. Anderson, Jeffrey A. Sosman, Cindy L. Vnencak-Jones, Kimberly B. Dahlman, William Pao*

*Corresponding author for this work

Research output: Contribution to journalReview article

44 Scopus citations

Abstract

Increased understanding of intertumoral heterogeneity at the genomic level has led to significant advancements in the treatment of solid tumors. Functional genomic alterations conferring sensitivity to targeted therapies can take many forms, and appropriate methods and tools are needed to detect these alterations. This review provides an update on genetic variability among solid tumors of similar histologic classification, using non-small cell lung cancer and melanoma as examples. We also discuss relevant technological platforms for discovery and diagnosis of clinically actionable variants and highlight the implications of specific genomic alterations for response to targeted therapy.

Original languageEnglish (US)
Pages (from-to)2264-2275
Number of pages12
JournalClinical Cancer Research
Volume20
Issue number9
DOIs
StatePublished - May 1 2014

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Beyond histology: Translating tumor genotypes into clinically effective targeted therapies'. Together they form a unique fingerprint.

  • Cite this

    Meador, C. B., Micheel, C. M., Levy, M. A., Lovly, C. M., Horn, L., Warner, J. L., Johnson, D. B., Zhao, Z., Anderson, I. A., Sosman, J. A., Vnencak-Jones, C. L., Dahlman, K. B., & Pao, W. (2014). Beyond histology: Translating tumor genotypes into clinically effective targeted therapies. Clinical Cancer Research, 20(9), 2264-2275. https://doi.org/10.1158/1078-0432.CCR-13-1591